215 related articles for article (PubMed ID: 16342656)
1. Aldosterone receptor antagonists in the medical management of chronic heart failure.
Tang WH; Parameswaran AC; Maroo AP; Francis GS
Mayo Clin Proc; 2005 Dec; 80(12):1623-30. PubMed ID: 16342656
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonists in heart failure.
Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonists for heart failure.
Richards AM
Expert Opin Pharmacother; 2011 Dec; 12(18):2801-15. PubMed ID: 22082128
[TBL] [Abstract][Full Text] [Related]
6. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Kalidindi SR; Tang WH; Francis GS
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
[TBL] [Abstract][Full Text] [Related]
7. The role of aldosterone receptor antagonists in the management of heart failure: an update.
Nagarajan V; Chamsi-Pasha M; Tang WH
Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
[TBL] [Abstract][Full Text] [Related]
8. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
9. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
12. Blocking aldosterone in heart failure.
Shafiq MM; Miller AB
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
[TBL] [Abstract][Full Text] [Related]
13. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
14. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
15. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Pitt B
J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone in the treatment of chronic heart failure.
Krum H; Liew D
Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone antagonists in heart failure.
Miller SE; Alvarez RJ
J Cardiovasc Nurs; 2013; 28(6):E47-54. PubMed ID: 23001067
[TBL] [Abstract][Full Text] [Related]
19. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Talatinian A; Chow SL; Heywood JT
Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
Nappi JM; Sieg A
Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
